Glucophage Unidie

Glucophage Unidie is a prescription medication that contains the active ingredient metformin hydrochloride. It is marketed in the European Union and is administered orally. As a biguanide antidiabetic agent, Glucophage Unidie is formulated to help manage blood glucose levels in adults with type 2 diabetes mellitus. The product does not include a specified strength or dosage form in the provided information as described by regulatory filings.

Glucophage Unidie is indicated for the long‑term management of hyperglycaemia in patients with type 2 diabetes mellitus, typically as part of a comprehensive treatment plan that includes diet and exercise.

- Used as monotherapy when diet and exercise alone do not achieve glycaemic targets. - Combined with other oral antidiabetic agents to improve overall glucose control. - May be prescribed when insulin therapy is not yet required. - Helps reduce hepatic glucose production and improve peripheral insulin sensitivity. - Often selected for patients who need a weight‑neutral antidiabetic option.

The safety profile of Glucophage Unidie reflects the typical effects observed with metformin therapy.

Common: - Nausea, abdominal discomfort, or diarrhoea. - Metallic taste in the mouth. - Decreased appetite. - Mild skin rash or itching.

Serious: - Lactic acidosis, a rare but potentially fatal metabolic complication. - Severe vitamin B12 deficiency leading to neuropathy. - Unexplained severe hypoglycaemia when combined with other glucose‑lowering agents.

When prescribing Glucophage Unidie, clinicians consider several safety factors to minimise risk.

- Assess renal function before initiation and periodically thereafter. - Avoid use in patients with acute or chronic metabolic acidosis, including diabetic ketoacidosis. - Monitor for signs of lactic acidosis, especially after major surgery or contrast imaging. - Evaluate vitamin B12 levels during long‑term therapy. - Use with caution in elderly patients or those with hepatic impairment. - Discontinue before any radiographic studies that use iodinated contrast agents.

Glucophage Unidie can interact with a variety of medicines, influencing its efficacy or safety.

Avoid: - Iodinated contrast media used in imaging studies. - Cimetidine, which can increase metformin plasma concentrations. - Certain antiretroviral drugs (e.g., didanosine) that may raise the risk of lactic acidosis.

Use with caution: - Other antidiabetic agents that may cause hypoglycaemia (e.g., sulfonylureas, insulin). - Diuretics that affect renal function. - ACE inhibitors or ARBs that can alter kidney perfusion. - Alcohol, which may increase the risk of lactic acidosis.